New Egrifta formulation picks up US FDA nod

Theratechnologies (Nasdaq: THTX) has received approval from the US Food and Drug Administration for Egrifta WR (tesamorelin), a new formulation for injection. The treatment is indicated for the reduction of excess abdominal fat in adults with HIV who have lipodystrophy.

The Montreal-based biopharma company said Egrifta WR will replace the current formulation, Egrifta SV. While both are daily injectables, the new version only needs to be reconstituted once a week and uses less than half the administration volume. The update is intended to improve convenience and simplify treatment for patients.

Tesamorelin remains the only drug approved in the USA for HIV-related lipodystrophy, a condition that often causes central adiposity. In clinical pharmacology studies, the Egrifta WR formulation was shown to be bioequivalent to the company’s original version.